ICER Analyses Increasingly Guide US Price Negotiations, Payers Report
Executive Summary
Nearly 65% of respondents reported ICER cost effectiveness reviews are 'likely' or 'extremely likely' to function as a benchmark in price negotiations with manufacturers, according to a recent survey.
You may also be interested in...
ICER Value Framework Update Reaffirms Support For Real-World Evidence
Drug makers have sought a larger role for RWE in ICER's review process; proposed update also includes process to re-evaluate cost-effectiveness evidence after one year.
ICER Value Assessments Could Provide US Standard, Payers, Providers Tell HHS
Comments to HHS on the Trump Administration’s US drug pricing blueprint recommend that cost effectiveness analyses by the Institute for Clinical and Economic Review could help promote value-based pricing.
FDA’s Real-World Evidence Project Finds That Pragmatic Clinical Trials Are Easier To DUPLICATE
Results from the US Food and Drug Administration’s RCT DUPLICATE demonstration are in. The findings both legitimize certain real-world evidence studies and also highlight the challenges involved in using RWE to replicate randomized clinical trials.